Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

Kai Michael Beeh,1 Anne-Marie Kirsten,2 Ana-Maria Tanase,3 Alexia Richard,3 Weihua Cao,4 Bettina Hederer,3 Jutta Beier,1 Oliver Kornmann,5 Richard N van Zyl-Smit6

1Insaf Respiratory Research Institute Wiesbaden, Wiesbaden, Germany; 2Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; 3Novartis Pharma AG, Basel, Switzerland; 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 5IKF Pneumologie, Clinical Research Centre Respiratory Diseases, Frankfurt, Germany; 6Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa

Background and purpose: Fixed-dose combinations of a long-acting beta agonist and an inhaled corticosteroid are more effective than the individual components in COPD. The primary study objective was to demonstrate that the combination indacaterol acetate/mometasone furoate (IND/MF [QMF149]) was non-inferior to the twice-daily combination salmeterol xinafoate/fluticasone propionate (Sal/Flu) in terms of trough FEV1 at week 12 (day 85). Secondary objectives were to compare the efficacy of IND/MF (QMF149) vs Sal/Flu with respect to other lung function parameters, COPD exacerbations, symptoms and dyspnea, health status/health-related quality of life, and rescue medication use.

Materials and methods: This was a 12-week multicenter, randomized, double-blind, double-dummy, parallel-group, Phase II study in patients with moderate-to-very-severe COPD, who were randomized (1:1) to IND/MF (QMF149) (150/160 µg once daily; n=316) or Sal/Flu (50/500 µg twice daily; n=313).

Results: Over 90% of patients completed the study: 94.6% in the IND/MF (QMF149) group and 92.0% in the Sal/Flu group. The primary objective of non-inferiority of IND/MF (QMF149) to Sal/Flu for trough FEV1 at week 12 (day 85) was met: the lower limit of the CI (95% CI: 27.7, 83.3 mL) was greater than -60 mL. The analysis for superiority of IND/MF (QMF149) to Sal/Flu demonstrated superiority of IND/MF (QMF149), with a difference of 56 mL (P<0.001). In addition, IND/MF (QMF149) treatment significantly improved COPD exacerbation-related parameters during the 12-week period. Other significant improvements with IND/MF (QMF149) vs Sal/Flu were noted for dyspnea at week 12 and other COPD symptoms and COPD rescue medication use over the 12 weeks. The safety and tolerability profiles of both the treatments were similar.

Conclusion: IND/MF (QMF149) (150/160 µg once daily) offered superior lung function and symptom efficacy and a favorable safety profile compared with Sal/Flu (50/500 µg twice daily) in patients with moderate-to-very severe COPD.

Keywords: COPD, once-daily inhalers, fixed-combination inhalers, indacaterol, mometasone, LABA/ICS combinations
**Plain language summary**

For the treatment of COPD, long-acting bronchodilators are the cornerstone of therapy, as recommended by the Global Initiative for Chronic Obstructive Lung Disease. For those with marked symptoms, particularly breathlessness and frequent exacerbations (increased cough and sputum), a combination of bronchodilators and/or adding an inhaled steroid is recommended. Inhaled steroids have been long-known to reduce exacerbations compared with a bronchodilator alone. This study assessed the efficacy of a once-daily long-acting bronchodilator/inhaled steroid (indacaterol acetate/mometasone furoate) compared with a twice-daily combination (salmeterol xinafoate/fluticasone propionate [Sal/Flu]) for the treatment of COPD. The study conclusively showed that once-daily indacaterol acetate/mometasone furoate combination improved lung function and reduced symptoms and exacerbations compared with twice-daily Sal/Flu combination.

**Introduction**

COPD is a major cause of chronic morbidity and mortality worldwide, and its management imposes a substantial economic burden, mainly due to the costs associated with managing exacerbations, especially hospitalizations. The main goals of treatment are to control symptoms and reduce the future risk of exacerbations. Current treatment recommendations suggest the use of inhaled corticosteroids (ICSs) as an add-on treatment for those patients who continue to exacerbate on effective bronchodilator.8

Most available long-acting beta agonist (LABA)/ICS combinations are formulated as twice-daily (bid) treatments based on the use of bid LABA formulations (salmeterol and formoterol). Vilanterol/fluticasone furoate is a LABA/ICS fixed-dose combination (FDC) that is suitable for once-daily (qd) dosing. Compared with vilanterol alone, the addition of fluticasone furoate to vilanterol has been shown to be associated with a decreased rate of moderate and severe exacerbations of COPD in patients with a history of exacerbation.9

QMF149, delivered via the Concept1 (Breezhaler®) device, is the combination of an investigational, inhaled qd FDC of the LABA indacaterol (IND) acetate (150 µg) and the ICS mometasone furoate (MF) (160 µg), initially developed for the maintenance treatment of COPD and asthma. Both the components of this LABA/ICS combination have shown clinical benefits in patients with COPD or asthma. Previous research demonstrated that 80, 160, and 320 µg doses of MF in the Concept1 (Breezhaler®) device were comparable with 200, 400, and 2×400 µg doses of MF, respectively, in the Twiskhaler® device; these findings were based on pharmacokinetic data in healthy volunteers, in vitro fine particle mass adjustments, and subsequent confirmation in a clinical study.15

MF is an on-target ICS due to its very high affinity for the glucocorticoid receptor. The efficacy of MF in COPD was demonstrated in a 52-week randomized controlled trial (RCT) comparing qd and bid administration in patients with moderate-to-severe COPD. This study reported that both MF 800 µg qd and MF 400 µg bid (administered via Twiskhaler®) significantly increased post-bronchodilator trough FEV₁ from baseline vs placebo (50 and 53 mL, respectively, vs a 19 mL decrease for placebo; P<0.001); in addition, health status, as measured by the St George’s Respiratory Questionnaire (SGRQ), improved significantly in all domains (total, activity, impacts, and symptoms) in the pooled MF groups vs placebo (P≤0.031).16 MF was generally well-tolerated, with incidence rates of any treatment-emergent adverse event (AE) comparable with placebo.16

Indacaterol is an ultra-LABA, the first approved for the treatment of COPD that allows qd administration, with a stronger affinity for the beta₂-adrenergic receptors vs a low intrinsic activity at the beta₂-receptor, which improves the cardiovascular safety profile; it has a fast onset of action (within 5 minutes) coupled with a sustained bronchodilator effect (24 hours). When compared with salbutamol (200 µg) and salmeterol/fluticasone propionate (50/500 µg) in patients with moderate-to-severe COPD, single doses of 150 and 300 µg indacaterol demonstrated a fast onset of action, similar to that of salbutamol and faster than that of salmeterol/fluticasone propionate; FEV₁ at 5 minutes post-dose was significantly higher with 150 and 300 µg indacaterol than it was with salmeterol/fluticasone propionate (50 mL, P=0.003; 70 mL, P<0.001, for the 150 and 300 µg dose, respectively).20

In clinical studies with a duration ranging from 12 weeks to 1 year, qd indacaterol 150 or 300 µg significantly improved lung function vs placebo in patients with moderate-to-severe COPD.17

In relation to safety, indacaterol has been reported to be well tolerated at all doses, with rates of AEs characteristic of beta₂-agonists, such as headache, muscle spasm, and tremor, comparable with placebo.17,21

The primary objective of the current study was to demonstrate that the investigational qd combination IND/MF (QMF149) is at least non-inferior to the bid combination salmeterol xinafoate/fluticasone propionate (Sal/Flu) in terms of trough FEV₁ at week 12 (day 85). Sal/Flu (50/500 µg, bid) is a marketed, FDC product comprising a LABA and ICS and is indicated for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD. The secondary objectives were to compare the efficacy of IND/MF (QMF149) vs Sal/Flu with respect
to other lung function parameters, COPD exacerbations, dyspnea (transitional dyspnea index [TDI]), health status/health-related quality of life (SGRQ; COPD assessment test [CAT]), rescue medication use and COPD symptoms, and to evaluate the safety and tolerability of study treatments during the treatment period.

Materials and methods
Study design
This was a multicenter, randomized, double-blind, double-dummy, parallel-group, Phase II study (NCT01636076), conducted between November 2, 2012, and September 25, 2013, at 117 study centers in Europe, Asia, Australia, South Africa, and the Middle East (see the list of all participating centers in Supplementary materials).

The study consisted of 1-week screening and 2-week run-in phase, followed by a double-blind, parallel-group treatment phase (12 weeks) and a 30-day safety follow-up (Figure 1). Written informed consent was obtained from all patients who participated, and the study was approved by the independent ethics committee/institutional review board of each study center. The study was conducted according to the ethical principles of the Declaration of Helsinki.

Patients
Patients were eligible for inclusion in the study if they were: male or female patients aged ≥40 years with moderate-to-very-severe COPD, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 guidelines,\(^2\) had a post-bronchodilator FEV\(_1\) of <70% of the predicted normal value,\(^23,24\) and a post-bronchodilator FEV\(_1\)/FVC of <0.70 at run-in (post-bronchodilator refers to within 30 minutes after inhalation of 400 µg salbutamol/360 µg albuterol [or equivalent dose]); current or ex-smokers with a smoking history of ≥10 pack years (number of packs of 20 cigarettes smoked per day multiplied by number of years the patient smoked, an ex-smoker was defined as a subject who had quit smoking ≥6 months prior to screening).

Key exclusion criteria included any COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the 6 weeks before screening or developing a COPD exacerbation between screening and randomization, any respiratory tract infection within 4 weeks prior to the screening visit or between the screening and baseline visits, concomitant pulmonary disease (eg, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension), a history of asthma or onset of respiratory symptoms before the age of 40 years. Patients who required the use of >8 inhalations of short-acting β\(_2\)-agonist (SABA) (90 µg albuterol/100 µg salbutamol via metered dose inhaler) on any 3 consecutive days or >12 inhalations of SABA on any 2 consecutive days from screening to randomization were also excluded from the study.

Treatments
At the start of the run-in period, patients were required to discontinue any previous ICS medication and bronchodilators (LABA and LAMA); patients receiving these treatments

![Figure 1](https://example.com/figure1.png)

**Figure 1** Study design.

**Notes:** Throughout the run-in phase, all patients received a LABA bid and SAMA (ipratropium) qid. At the start of the run-in period, patients were required to discontinue any previous ICS medication and qd bronchodilators (LABA and LAMA; patients receiving these treatments had to be switched at the screening visit to LABA bid or SAMA qid, respectively). Indacaterol (LABA qd) had to be switched at the screening visit to LABA bid. A minimum of a 48-hour washout period for LABA bid and 8 hours for SAMA prior to the spirometry assessment at the run-in and randomization visits were maintained. Patients were contacted for safety evaluations during the 30 days following the last study visit or following the last administration of study treatment if there were post-treatment follow-up visits (whichever was later), including a final contact at the 30-day point.

**Abbreviations:** qd, once-daily; bid, twice-daily; qid, four times daily; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; SAMA, short-acting muscarinic antagonist; IND/MF, indacaterol acetate/mometasone furoate; Sal/Flu, salmeterol xinafoate/fluticasone propionate.
were switched to a LABA bid and short-acting muscarinic antagonist (SAMA; ipratropium) four times daily. Following the run-in period, eligible patients were randomized (1:1), using Interactive Response Technology, to one of the two treatment groups: IND/MF (QMFI49) (150/160 µg qd), delivered via the Concept1 (Breezhaler®) device as a single dose dry powder inhaler, or Sal/Flu (50/500 µg bid), delivered via the Diskus®/Accuhaler® device.

Randomization was stratified by smoking history (ex-smoker, current smoker) and COPD severity (moderate, severe, very severe). IND/MF (QMFI49) was supplied by Novartis Drug Supply Management (Novartis International AG, Basel, Switzerland) as dry powder FDC formulation.

As IND/MF (QMFI49) and Sal/Flu are delivered via different inhaler devices, a double-dummy design was used for dosing, whereby patients received two inhalers. They were instructed to take both morning and evening doses at approximately the same time of day (both in the morning and evening). The morning dosing consisted of sequential single inhalations from each of the two devices: one inhalation from the Concept1 (Breezhaler®) device containing IND/MF (QMFI49) or placebo plus one inhalation from the Diskus®/Accuhaler® device containing Sal/Flu or placebo. The evening dosing consisted of only a single inhalation from the Diskus®/Accuhaler® device containing Sal/Flu or placebo.

All patients, physicians, and other study staff were blinded to the assigned treatment for the duration of the study.

Outcomes and assessments

Spirometry was performed using standard methodology. The primary endpoint was trough FEV₁, after 12 weeks of treatment (day 85). For IND/MF (QMFI49), trough FEV₁ refers to the mean of the two FEV₁ values measured at 23 hours 10 minutes and 23 hours 45 minutes after the previous morning dose. For Sal/Flu, trough FEV₁ is defined as the mean of the two FEV₁ values measured at 11 hours 10 minutes and 11 hours 45 minutes after the previous evening dose.

Secondary endpoints included absolute value of trough FEV₁ value at week 12, area under the curve (AUC) (5 minutes to 4 hours) for FEV₁ on day 1, COPD exacerbation-related parameters (time to first COPD exacerbation during the 12-week treatment, the annual rate of COPD exacerbations, duration [total days] of COPD exacerbations over the 12-week treatment period), TDI²⁵ focal score and the proportion of responders at week 12 (day 84), SGRQ²⁶ total score and the proportion of responders at week 12 (day 84), CAT²⁷ frequencies of categories of clinical impact on COPD (mild, moderate, severe, or very severe) at week 12 (day 84), COPD rescue medication use over 12 weeks of treatment (electronic diary [e-diary]), COPD symptoms (e-diary) over 12 weeks (daily respiratory symptoms [change from baseline in the mean daily respiratory symptom scores], percentage of days “able to perform usual daily activities,” percentage of nights with “no night-time awakenings,” percentage of days with “no daytime symptoms”), and safety assessments.

A COPD exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume, sputum purulence, or a worsening of any one major symptom together with an increase in any one of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough, wheeze. A COPD exacerbation was considered of moderate severity if treatment with systemic corticosteroids and/or antibiotics was required; it was considered severe if the patient was hospitalized.

Other exacerbation-related parameters are presented in the Supplementary materials, Table S1.

The degree of impairment due to dyspnea was assessed at baseline, using the Baseline Dyspnea Index, and over the treatment period using the TDI, which captures changes from baseline; a TDI focal score of ≥1 is considered to be a clinically significant improvement from baseline.²⁸ Health status/health-related quality of life was assessed with the SGRQ²⁶ and CAT;²⁷ for SGRQ, a 4-unit change is classed as a minimally clinical important difference (MCID).²⁹ At the run-in visit (day 14), all patients were provided with an e-diary to record morning and evening daily clinical symptoms and rescue medication (salbutamol/albuterol) use. The patient was instructed to routinely complete the diary twice daily, in the morning and evening, considering events over the previous 12 hours.

Statistical analysis

The sample size was determined to demonstrate the non-inferiority of IND/MF over Sal/Flu with regard to trough FEV₁ after 12 weeks of treatment. With a non-inferiority margin of ~60 mL, an SD of 210 mL, and dropout rate of 10%, ~288 patients were needed per arm to yield 90% power for the testing of non-inferiority with a one-sided significance level of 2.5%. nQuery (V7.0) was used to calculate the sample sizes.

The full analysis set (FAS) was used for the primary efficacy analysis and included all randomized patients who
received at least one dose of the study drug (intent-to-treat principle).

Primary and most of the secondary endpoint analyses were performed using a mixed model for repeated measures (MMRM). The model comprised treatment, country, visit, treatment-by-visit interaction, smoking status, and COPD severity as fixed effects, and baseline FEV₁ and SABA FEV₁ reversibility components as covariates.

The between-treatment comparisons for AUC (5 minutes to 4 hours) for FEV₁ on day 1 were analyzed with analysis of covariance (ANCOVA) mixed model.

The time to first COPD exacerbation was displayed with a Kaplan–Meier curve and analyzed using a Cox regression model stratified by baseline smoking status and COPD severity. The rate of COPD exacerbations over the 12-week treatment period was analyzed using a negative binomial regression model displaying 95% CI of the estimated rate difference. The duration and total number of exacerbation days were summarized by treatment using subjects with at least one exacerbation.

Logistic regression was conducted for TDI focal score on the proportion of patients achieving clinically meaningfulness as ≥1 unit and SGRQ for the proportion of subjects who achieved a clinically important improvement of at least 4 units in the SGRQ total score after 12 weeks of treatment. The CAT frequencies of categories of clinical impact on COPD (mild, moderate, severe, or very severe) were summarized by treatment.

Between-treatment comparisons for change from baseline in the mean daily total and mean daily individual symptom scores over the 12 weeks of treatment were analyzed with ANCOVA mixed model.

Non-inferiority of IND/MF (QMF149) to Sal/Flu would be claimed if the 95% CI for the adjusted mean FEV₁ difference of IND/MF (QMF149) minus Sal/Flu lay entirely to the right (higher than) of the non-inferiority margin of −60 mL. If non-inferiority of IND/MF (QMF149) with respect to trough FEV₁ after 12 weeks treatment (ie, at day 85) was met, IND/MF (QMF149) was then tested for superiority using the FAS at the (two-sided) 5% significance level by the same MMRM used for the primary analysis.

The exploratory subgroup analyses of trough FEV₁ after 12 weeks of treatment were performed for FAS by using the MMRM analysis in the following subgroups of interest: age group (<65 years, 65 to <75 years, ≥75 years), gender (male, female), race (Caucasian, non-Caucasian), severity of airflow limitation (moderate or less, severe or worse, based on the classification defined by the GOLD 2011 guidelines), smoking status at baseline (current smoker, ex-smoker), and

SABA FEV₁ reversibility (≤5% increase, >5% and ≤12% increase, >12% increase).

The safety set included all patients who received at least one dose of study drug.

SAS (V9.3) was used for all the statistical analyses conducted in this study.

Results

Patients

Of the 982 patients screened, 629 with moderate-to-very severe COPD were randomized (1:1) to one of the two treatment groups: IND/MF (QMF149), n=316; Sal/Flu, n=313 (Figure 2). Over 90% of patients in both the treatment groups completed the study: 94.6% in the IND/MF (QMF149) group and 92.0% in the Sal/Flu group. Overall, the most common reasons for treatment discontinuation were patient/guardian decision (n=17, 2.7%) and AEs (n=17, 2.7%). Patient demographics and baseline characteristics were similar between the two treatment groups (Table 1). The average age of the study population was 64.5 years, and over 90% of patients were aged between 40 and 75 years.

The numbers of patients using ICS (either as an FDC or monotherapy) at screening were comparable between the treatment groups: IND/MF (QMF149), n=140 (44.3%); Sal/Flu, n=138 (44.1%). Most of the patients had severe (IND/MF [QMF149], 48.7%; Sal/Flu, 43.1%) or very severe (IND/MF [QMF149], 9.5%; Sal/Flu, 11.5%) disease; 40.2% of patients in the IND/MF (QMF149) group and 45.0% in the Sal/Flu group were categorized as moderate severity (GOLD 2011),² with a mean duration of COPD of ~8 years in both the groups. As per protocol, all patients were smokers or ex-smokers (mean 45 pack years).

FEV₁ at screening was balanced across the two groups, with a mean post-bronchodilator FEV₁ of 1.28 L in the IND/MF (QMF149) group and 1.30 L in the Sal/Flu group and a mean percent predicted FEV₁ of 46.3% and 46.7% of the predicted normal, respectively. The majority of patients had no COPD exacerbations in the previous year since this was not a study inclusion criterion. Similar numbers of patients in each treatment group had at least one COPD exacerbation in the previous year (103 patients [32.6%] in the IND/MF [QMF149] group, 114 [36.4%] in the Sal/Flu group).

Efficacy

Lung function

Trough FEV₁

At week 12 (day 85), the least squares (LS) mean trough FEV₁ for IND/MF (QMF149) was 1.270 L (± standard error 0.0124)
Figure 2 Summary of patient disposition.

**Abbreviations:** IND/MF, indacaterol acetate/mometasone furoate; Sal/Flu, salmeterol xinafoate/fluticasone propionate.

Table 1 Patient demographics and clinical characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>IND/MF (QMF149) (n=316)</th>
<th>Sal/Flu (n=313)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>64.8 (7.74)</td>
<td>64.1 (7.89)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>233 (73.7)</td>
<td>227 (72.5)</td>
</tr>
<tr>
<td>Female</td>
<td>83 (26.3)</td>
<td>86 (27.5)</td>
</tr>
<tr>
<td>Ethnicity, Caucasian, n (%)</td>
<td>273 (86.4)</td>
<td>276 (88.2)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.2 (4.88)</td>
<td>26.3 (4.98)</td>
</tr>
<tr>
<td>Smoking status at baseline, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>197 (62.3)</td>
<td>189 (60.4)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>119 (37.7)</td>
<td>124 (39.6)</td>
</tr>
<tr>
<td>Severity of COPD, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>127 (40.2)</td>
<td>141 (45.0)</td>
</tr>
<tr>
<td>Severe</td>
<td>154 (48.7)</td>
<td>135 (43.1)</td>
</tr>
<tr>
<td>Very severe</td>
<td>30 (9.5)</td>
<td>36 (11.5)</td>
</tr>
<tr>
<td>Duration of COPD, years</td>
<td>8.4 (6.76)</td>
<td>7.8 (5.73)</td>
</tr>
<tr>
<td>Number of COPD exacerbations in the previous year, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>210 (66.5)</td>
<td>197 (62.9)</td>
</tr>
<tr>
<td>1</td>
<td>78 (24.7)</td>
<td>84 (26.8)</td>
</tr>
<tr>
<td>≥2</td>
<td>25 (7.9)</td>
<td>30 (9.6)</td>
</tr>
<tr>
<td>ICS use at screening, n (%)</td>
<td>140 (44.3)</td>
<td>138 (44.1)</td>
</tr>
<tr>
<td>FEV₁ pre-bronchodilator at screening, L</td>
<td>1.16 (0.39)</td>
<td>1.18 (0.44)</td>
</tr>
<tr>
<td>FEV₁ pre-bronchodilator at screening (% predicted)</td>
<td>41.76 (11.85)</td>
<td>42.40 (12.26)</td>
</tr>
<tr>
<td>FEV₁ post-bronchodilator at screening, L</td>
<td>1.28 (0.40)</td>
<td>1.30 (0.47)</td>
</tr>
<tr>
<td>FEV₁ post-bronchodilator at screening (% predicted)</td>
<td>46.35 (12.11)</td>
<td>46.69 (12.64)</td>
</tr>
</tbody>
</table>

**Note:** Data are presented as mean (SD), unless otherwise stated.

**Abbreviations:** BMI, body mass index; ICS, inhaled corticosteroid; IND/MF, indacaterol acetate/mometasone furoate; Sal/Flu, salmeterol xinafoate/fluticasone propionate.
and for Sal/Flu, it was 1.215 L (±0.0124). As the lower limit of the treatment difference (IND/MF – Sal/Flu = 56 mL; 95% CI: 27.7, 83.3 mL) was greater than –60 mL at week 12 (day 85), the primary end point was met: IND/MF (QMF149) was shown to be non-inferior to Sal/Flu with respect to trough FEV₁. Because the study met its primary objective of non-inferiority to Sal/Flu, testing for superiority of IND/MF (QMF149) to Sal/Flu was conducted. This analysis demonstrated superiority of IND/MF (QMF149) to Sal/Flu, with a treatment difference of 56 mL (P, 0.001).

IND/MF (QMF149) provided greater and sustained trough FEV₁ improvements compared with Sal/Flu increasing from day 2 onwards, over the 12-week period (Figure 3). Mean FEV₁ on days 28, 29, and 84 was significantly greater with IND/MF (QMF149) vs Sal/Flu: day 28, 44 mL (95% CI 18.4, 70.2; P<0.001); day 29, 30 mL (95% CI 3.8, 56.1; P=0.025); and day 84, 62 mL (95% CI 32.4, 90.6; P<0.001). There was a small, but significant, efficacy difference in the mean trough FEV₁ in favor of Sal/Flu observed at day 2 (–27 mL; 95% CI –47.2, –6.3; P=0.011).

**Exploratory subgroup analyses**

Subgroup analyses results for trough FEV₁ were consistent and further supported the primary endpoint in terms of age, gender, race, COPD severity, smoking status, and FEV₁ reversibility, with IND/MF (QMF149) demonstrating significant improvements in trough FEV₁ at week 12 (day 85) in the subgroups of interest (Table 2).

**AUC (5 minutes to 4 hours) for FEV₁ on day 1**

There was a significant treatment difference between IND/MF (QMF149) and Sal/Flu in FEV₁ AUC (5 minutes to 4 hours) on day 1, in favor of IND/MF (QMF149), with LS mean of 17 mL (95% CI 0.9, 33.8 mL; P=0.039). IND/MF (QMF149) showed faster onset of bronchodilation effect, as evidenced by greater LS mean FEV₁ values in the IND/MF (QMF149) group vs

| Table 2 Exploratory subgroup analyses for trough FEV₁ after 12 weeks of treatment |
|---------------------------------|---------------------------------|
| Subgroup of interest            | Results                          |
| Age                             | • LS mean improvements in both age groups (<65 and ≥65 years): 45 mL (P=0.040) and 63 mL (P<0.001), respectively |
| Gender                          | • Males – LS mean improvement of 61 mL (P<0.001) |
|                                 | • Due to the small sample size, IND/MF (QMF149) only demonstrated numerical improvements in females, with a LS mean improvement of 41 mL (NS) |
| Race                            | • LS mean improvements in both Caucasian and non-Caucasian patients: 51 mL (P=0.001) and 88 mL (P=0.012), respectively |
| Severity of airflow limitation  | • LS mean improvements in both groups defined by baseline COPD severity (moderate or less, severe or worse): 54 mL (P=0.031) and 51 mL (P=0.002), respectively |
| Smoking status at baseline      | • LS mean improvement of 63 mL in ex-smokers (P<0.001) |
|                                 | • IND/MF (QMF149) demonstrated numerical improvements in current smokers, with an LS mean improvement of 35 mL (NS) |
| Short-acting bronchodilator FEV₁ | • LS mean improvements in all three groups defined by FEV₁ reversibility (≥5% increase, 5%–12% increase, and >12% increase): 50 mL (P=0.049), 74 mL (P=0.021), and 51 mL (P=0.014), respectively |

**Abbreviations:** IND/MF, indacaterol acetate/mometasone furoate; LS, least squares; NS, not significant.
the Sal/Flu group at 5 minutes, 30 minutes, and 1 hour post-dose on day 1; the treatment differences (56, 31, and 24 mL) were significant at all these time points ($P<0.001$ at 5 and 30 minutes; $P<0.0061$ at 1 hour post-dose); at 4 hours after dosing, a similar improvement in lung function was observed in LS mean FEV$_1$ in both the treatment groups (Figure 4).

Exacerbations

Exacerbation rates were low in both the groups, with a mean of 0.25, 0.11, and 0.36 for moderate, severe, and moderate or severe exacerbations, per patient per year, respectively, in the IND/MF (QMF149) group vs 0.59, 0.07, and 0.66, respectively, in the Sal/Flu group. For all the COPD exacerbation-related parameters reported below, no significant differences between treatment groups were noted for severe COPD exacerbations.

Time to first COPD exacerbation during the 12-week treatment

Patients in the IND/MF (QMF149) group demonstrated a significantly longer time to first moderate, and first moderate or severe exacerbation compared with patients in the Sal/Flu group: HR =0.45 (95% CI 0.250, 0.815; $P=0.008$); HR =0.51 (95% CI 0.298, 0.855; $P=0.011$; Figure 5), with reductions in HR of 55% and 49%, respectively.

The IND/MF (QMF149) group demonstrated higher event-free rates (HR <1) at week 12 than did the Sal/Flu group for moderate, and moderate or severe exacerbations (Table 3).

Annual rate of COPD exacerbations

The annualized exacerbation rates were compared between groups and the reductions in annual rate of moderate (56%;
and moderate or severe (44%; \( P = 0.005 \)), and moderate or severe (44%; \( P = 0.028 \)) COPD exacerbations were significantly in favor of IND/MF (QMF149) (Table 3).

**Duration (total days) of COPD exacerbations over the 12-week treatment period**

Most patients did not experience a COPD exacerbation during the treatment period. IND/MF (QMF149) significantly reduced the mean (±SD) number of exacerbation days per patient compared with Sal/Flu for moderate (0.9±4.40 vs 1.5±5.05, \( P = 0.003 \)), and for moderate or severe (1.4±6.57 vs 1.7±5.29, \( P = 0.015 \)) COPD exacerbations.

**Dyspnea**

IND/MF (QMF149) significantly improved TDI focal score at week 12 (least squares mean for treatment difference [LSMTD] = 0.501; 95% CI 0.0601, 0.9414; \( P = 0.026 \)) vs Sal/Flu. There was no significant difference between groups in the percentage of patients who achieved MCID ≥ 1 point from baseline in TDI focal score at week 12, although this was numerically in favor of IND/MF (QMF149): 52.6% in the IND/MF (QMF149) group vs 45.9% in the Sal/Flu group.

**Health status/health-related quality of life**

There were no significant differences in health status/health-related quality of life between the two treatment groups after 12 weeks of treatment.

**SGRQ**

Treatment with IND/MF (QMF149) was associated with numerical improvements in health status (SGRQ total score) after 12 weeks of treatment compared with treatment with Sal/Flu (LSMTD − 1.66; 95% CI − 3.6001, 0.2777; NS). Unlike the Sal/Flu group (− 1.94 units), the IND/MF (QMF149) group approached a clinically meaningful improvement in patient health status from baseline (− 3.6 units) in the SGRQ total score.

There was no significant difference between groups in the percentage of patients achieving MCID ≥ 4 units in the SGRQ score at week 12 (day 84), although a numerically higher proportion of patients (42.7%) in the IND/MF (QMF149) group achieved this compared with the Sal/Flu group (37.5%).

**CAT**

CAT scores of 0–10, 11–20, 21–30, and 31–40 represent a “mild,” “moderate,” “severe”, or “very severe” clinical impact of COPD on the patient, respectively. At week 12 (day 84), fewer patients in the IND/MF (QMF149) group than in the Sal/Flu group were in the “severe” (23.4% vs 24.3%) or “very severe” (1.6% vs 4.5%) clinical impact of COPD categories.

**COPD rescue medication use**

The reduction in rescue medication use over 12 weeks was significantly in favor of IND/MF (QMF149) vs Sal/Flu.
Table 4 Rescue medication use over 12 weeks of treatment

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Treatment difference</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily number of puffs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND/MF (QMF149)</td>
<td>-0.470</td>
<td>(-0.7795, -0.1613)</td>
<td>0.003</td>
</tr>
<tr>
<td>Sal/Flu</td>
<td>-0.1612</td>
<td>0.1573</td>
<td></td>
</tr>
<tr>
<td>Daytime number of puffs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND/MF (QMF149)</td>
<td>-0.325</td>
<td>(-0.5239, -0.1256)</td>
<td>0.001</td>
</tr>
<tr>
<td>Sal/Flu</td>
<td>-0.1026</td>
<td>0.0104</td>
<td></td>
</tr>
<tr>
<td>Nighttime number of puffs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND/MF (QMF149)</td>
<td>-0.143</td>
<td>(-0.2834, -0.0036)</td>
<td>0.044</td>
</tr>
<tr>
<td>Sal/Flu</td>
<td>0.0751</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% of days with no rescue medication use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND/MF (QMF149)</td>
<td>6.259</td>
<td>(1.7086, 10.8084)</td>
<td>0.007</td>
</tr>
<tr>
<td>Sal/Flu</td>
<td>2.3980</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: IND/MF, indacaterol acetate/mometasone furoate; LS, least squares; SE, standard error of the mean; Sal/Flu, salmeterol xinafoate/fluticasone propionate; mean, least squares mean.

(Table 4): mean daily number of puffs (LSMTD −0.47, \( P=0.003 \)), mean daytime number of puffs (LSMTD −0.325, \( P=0.001 \)), mean nighttime number of puffs (LSMTD −0.143, \( P=0.044 \)), and percentage of days with no rescue medication use (LSMTD 6.26, \( P=0.007 \)).

COPD symptoms

Compared with Sal/Flu treatment, IND/MF (QMF149) therapy significantly reduced the mean daily respiratory symptoms score (LSMTD −0.122; 95% CI −0.2108, −0.0339; \( P=0.007 \)), the percentage of days “able to perform usual daily activities” (LSMTD 7.537%; 95% CI 3.8326, 11.2424; \( P<0.001 \)) and the percentage of nights with “no nighttime awakenings” (LSMTD 3.507%; 95% CI 0.0121, 7.0022; \( P=0.049 \)) over 12 weeks (Table 5). There was no significant difference in terms of percentage of days with “no daytime symptoms” over 12 weeks of treatment (Table 5).

Safety and tolerability

Overall, both the treatments were well-tolerated, with a low incidence of AEs. No deaths were reported in this study. Most of the reported AEs were of mild to moderate severity.

Table 5 Electronic diary COPD symptoms – change from baseline

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Treatment difference</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily respiratory symptoms score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND/MF (QMF149)</td>
<td>-0.443</td>
<td>(-2.5626, 1.6771)</td>
<td>0.682</td>
</tr>
<tr>
<td>Sal/Flu</td>
<td>1.0791</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% of days “able to perform usual daily activities”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND/MF (QMF149)</td>
<td>1.155</td>
<td>1.0686</td>
<td>0.0467</td>
</tr>
<tr>
<td>Sal/Flu</td>
<td>1.0791</td>
<td>1.0467</td>
<td></td>
</tr>
<tr>
<td>% of nights with “no nighttime awakenings”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND/MF (QMF149)</td>
<td>7.242</td>
<td>3.507</td>
<td>1.7789</td>
</tr>
<tr>
<td>Sal/Flu</td>
<td>3.735</td>
<td>1.8292</td>
<td></td>
</tr>
<tr>
<td>% of days with “no daytime symptoms”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND/MF (QMF149)</td>
<td>1.155</td>
<td>1.0686</td>
<td>0.0467</td>
</tr>
<tr>
<td>Sal/Flu</td>
<td>1.0791</td>
<td>1.0467</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: IND/MF, indacaterol acetate/mometasone furoate; LS, least squares; SE, standard error of the mean; Sal/Flu, salmeterol xinafoate/fluticasone propionate; mean, least squares mean.
intensity and were resolved by the last follow-up visit. IND/MF (QMF149)-treated patients experienced fewer serious adverse events (SAEs), AEs, and AEs related to COPD exacerbations, as well as discontinuations due to AEs, compared with Sal/Flu-treated patients (Table 6).

The most common SAE was COPD exacerbation: 1.9% (n=6) in the IND/MF (QMF149) group and 1.6% (n=5) in the Sal/Flu group. COPD exacerbation was also the most common AE leading to discontinuation in either treatment group: 0.6% (n=2) in the IND/MF (QMF149) group and 0.3% (n=1) in the Sal/Flu group. The incidence of pneumonia (any reported AE or SAE of pneumonia confirmed by chest X-ray) was low and similar between the two treatment groups: IND/MF (QMF149) (n=3; 0.9%); Sal/Flu (n=5; 1.6%). Likewise, the incidence of AEs related to cardiac disorders was comparable: IND/MF (QMF149) (n=11; 3.5%); Sal/Flu (n=8; 2.6%). The incidences of rhinitis, cough, and headache were low but slightly higher in the IND/MF vs Sal/Flu treatment arms (2.5% vs 0.6%, 3.2% vs 1.6%, and 3.2% vs 1.6%, respectively). No major effects of treatment on pulse or blood pressure were observed, and no clinically meaningful treatment differences were noted between the treatment groups for routine laboratory parameters.

### Table 6 Most frequent treatment-emergent AEs (≥1% in any treatment group) by preferred term or primary system organ class (safety set)

<table>
<thead>
<tr>
<th>Term</th>
<th>IND/MF (QMF149) (n=316), n (%)</th>
<th>Sal/Flu (n=313), n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any AE&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>132 (41.8)</td>
<td>139 (44.4)</td>
</tr>
<tr>
<td>SAE&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>10 (3.2)</td>
<td>19 (6.1)</td>
</tr>
<tr>
<td>Discontinuation due to any AE&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>6 (1.9)</td>
<td>11 (3.5)</td>
</tr>
<tr>
<td>COPD exacerbations</td>
<td>24 (7.6)</td>
<td>47 (15)</td>
</tr>
<tr>
<td>Nasopharyngitis&lt;sup&gt;a&lt;/sup&gt;</td>
<td>12 (3.8)</td>
<td>8 (2.6)</td>
</tr>
<tr>
<td>Cough&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10 (3.2)</td>
<td>5 (1.6)</td>
</tr>
<tr>
<td>Headache&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10 (3.2)</td>
<td>5 (1.6)</td>
</tr>
<tr>
<td>Rhinitis&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8 (2.5)</td>
<td>2 (0.6)</td>
</tr>
<tr>
<td>Dyspnea&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7 (2.2)</td>
<td>10 (3.2)</td>
</tr>
<tr>
<td>Pneumonia&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3 (0.9)</td>
<td>5 (1.6)</td>
</tr>
<tr>
<td>Cardiac disorders&lt;sup&gt;b&lt;/sup&gt;</td>
<td>11 (3.5)</td>
<td>8 (2.6)</td>
</tr>
</tbody>
</table>

Notes: AE by preferred term; "AE by primary system organ class. A patient with multiple AEs is counted only once in the “any AE” row. A patient with multiple AEs within a preferred term is counted only once for that preferred term. A patient with multiple AEs within a primary system organ class is counted only once for that system organ class. All AEs starting on or after the time of first administration of double-blind study drug but not later than 7 days (30 days in the case of a SAE) after the last administration are included in the summaries.

Abbreviations: AE, adverse event; IND/MF, indacaterol acetate/mometasone furoate; SAE, serious adverse event; Sal/Flu, salmeterol xinafoate/fluticasone propionate.

### Discussion

This randomized, parallel-group, 12-week study of the qd combination of IND/MF (QMF149) delivered via the Concept1 (Breezhaler<sup>®</sup>) device demonstrated significant improvements in lung function, as measured by the primary endpoint of trough FEV<sub>1</sub>, compared with bid Sal/Flu delivered via the Diskus®/Accuhaler<sup>®</sup> device, in patients with moderate-to-very-severe COPD. Secondary endpoints, including exacerbations, dyspnea, rescue medication use, COPD symptoms, showed superior efficacy of IND/MF over Sal/Flu.

For the primary endpoint of trough FEV<sub>1</sub>, at week 12 (day 85), treatment with IND/MF (QMF149) resulted in a 56 mL improvement over Sal/Flu. An increased improvement in trough FEV<sub>1</sub> for IND/MF (QMF149) over Sal/Flu was observed after day 2 of treatment. The exploratory subgroup analyses, which were conducted for several subgroups of interest (age, gender, race, COPD severity, smoking status, and FEV<sub>1</sub> reversibility), showed similar results to those of the primary analysis for trough FEV<sub>1</sub> after 12 weeks of treatment, further supporting the superiority of IND/MF (QMF149) to Sal/Flu.

Importantly, the fast onset of action of the LABA component of QMF149, indacaterol<sup>30</sup> was confirmed in favor of IND/MF (QMF149) over Sal/Flu, as significant treatment differences were observed for LS means of FEV<sub>1</sub> at 5 minutes, 30 minutes, and 1 hour post-dose on day 1. Indacaterol provides 24-hour bronchodilation,<sup>17,30</sup> and when compared with other LABAs, such as salmeterol and formoterol, it has shown superior improvements in lung function, dyspnea, and rescue medication use in patients with COPD.<sup>30-32</sup>

The treatment difference in trough FEV<sub>1</sub> observed in the current study with the FDC combination of IND/MF (QMF149) vs Sal/Flu is similar to findings in previous studies comparing indacaterol monotherapy with salmeterol monotherapy. Specifically, indacaterol (150 µg qd) was significantly superior to salmeterol 50 µg bid at week 12 in patients with moderate-to-severe COPD: trough FEV<sub>1</sub> (adjusted mean difference [95% CI] 60 [37, 83] mL; P<0.001).<sup>31</sup> Similarly, an earlier study that compared indacaterol (150 µg qd) with salmeterol (50 µg bid) and placebo in moderate-to-severe COPD found that indacaterol increased trough FEV<sub>1</sub> by 60 mL improvement over Sal/Flu to very-severe COPD. Secondary endpoints, including exacerbations, dyspnea, rescue medication use, COPD symptoms, showed superior efficacy of IND/MF over Sal/Flu.

The present study evaluated COPD patients with moderate (42%), severe (46%), and very severe (11%) disease (GOLD categories B, C, and D; GOLD 2014),<sup>30</sup> so compared with patients in the previous studies of indacaterol vs salmeterol,<sup>30,32</sup> the patients in the current study had generally more advanced disease. However, they were
comparable with the population in the INVIGORATE study, where indacaterol alone was less effective than tiotropium for reducing exacerbations.44

In patients with more severe disease and persistent exacerbations, treatment with a single bronchodilator (LABA or LAMA) may not be sufficient; hence, those patients may benefit from dual bronchodilation or a combination of LABA and ICS, the latter preferred for patients with a history of or concomitant asthma.8 Support for the contribution of the ICS MF to the lung function efficacy of a LABA/ICS combination is provided by the pooled analysis of two 52-week RCTs of formoterol fumarate/mometasone furoate (FF/MF) FDC combination in patients with moderate-to-very-severe COPD.35 This study found that the improvements in trough FEV₁ were significantly greater for FF/MF 10/400 µg compared with FF 10 µg (P<0.008) and placebo (P<0.001) at the week 13 primary endpoint and at all other time points (eg, week 26).

An important aspect of COPD management is reducing or preventing COPD exacerbations;24 due to their substantial and potentially prolonged negative impact on patients, the possible acceleration in disease progression and considerable healthcare expenditure.56 Limitations of the current study, in terms of the secondary endpoint of exacerbations, include its short duration of 12 weeks and the fact that the inclusion criteria did not require a history of exacerbations, resulting in low exacerbation rates, which prevent firm conclusions on long-term exacerbation outcomes. Nevertheless, IND/ MF (QMF149) treatment significantly improved COPD exacerbation-related parameters for moderate, and moderate or severe exacerbations during the 12-week treatment period. These findings should be interpreted with caution, but may show a trend for long-term outcomes. An earlier study in patients with moderate COPD who were at low risk of exacerbations – the Indacaterol: Switching Non-exacerbating Patients with Moderate COPD From Salmeterol/ Fluticasone to Indacaterol (INSTEND) trial – demonstrated non-inferiority in terms of trough FEV₁ after 12 weeks of indacaterol 150 µg qd monotherapy to the combination of Sal/Flu 50/500 µg bid; this study also found no significant differences between the monotherapy to the combination treatment group on TDI or the SGRQ at weeks 12 or 26, or rescue medication use or COPD exacerbation rates over 26 weeks.37

Other significant improvements with IND/MF (QMF149) vs Sal/Flu were noted for dyspnea (TDI focal score) at week 12, COPD rescue medication use (number of puffs of salbutamol/albuterol) over the 12 weeks, as well as COPD symptoms (daily respiratory symptoms score, the percentage of days “able to perform usual daily activities” and the percentage of nights with “no nighttime awakenings”) over 12 weeks.

Although health status/health-related quality of life (as determined by the SGRQ total score and the CAT overall score) did not show clinically significant improvements with either treatment after 12 weeks, the IND/MF (QMF149) group approached the meaningful clinical improvement difference (MCID) of ≥4 units39 in patient health status from baseline (3.6 units) in the SGRQ total score. There was also no significant difference between groups in the proportion of patients who achieved MCID >1 point from baseline in TDI focal score or MCID ≥4 units in the SGRQ score at week 12.

Overall, the efficacy findings of the present study are in agreement with those from systematic reviews, which have supported the use of LABA/ICS combination therapies in COPD.2,38,39

In patients with moderate-to-very-severe COPD and exacerbations, an ICS combined with a LABA is more effective than either component alone in improving lung function and health status and reducing exacerbations.8

The safety and tolerability profiles of both the treatments were similar. Both the treatments were generally well-tolerated, with COPD exacerbations, nasopharyngitis, and cough being the most commonly reported AEs. AEs related to COPD exacerbation occurred nearly twice as frequently in the Sal/Flu group compared with the IND/MF (QMF149) group: 47 (15%) and 24 (7.6%), respectively.

Lastly, in addition to the superior efficacy of qd IND/ MF (QMF 149) vs bid Sal/Flu, the qd dosing of the IND/MF (QMF149) combination offers greater patient convenience.

**Conclusion**

In summary, this Phase II study showed that the LABA/ICS FDC treatment, IND/MF (QMF149) (150/160 µg qd, delivered via Concept1 [Breezhaler®]), offered superior efficacy and a similar safety profile compared with Sal/Flu (50/500 µg bid, delivered via Diskus®/Accuhaler®) in patients with moderate-to-very severe COPD. IND/MF (QMF149) could potentially represent an improvement in ICS-based treatment for COPD, as it combines the rapid onset of action and “best in class” efficacy of the LABA indacaterol, along with the anti-inflammatory activity of the ICS MF.

In line with GOLD recommendation, LABA/ICS would benefit a rather limited group of COPD patients (eg, who may have a history of asthma and/or findings suggestive of
asthma–COPD overlap) while in asthma ICS-based treatment is the cornerstone therapy and therefore IND/MF (QMF149) is currently developed for asthma.

Data sharing
Novartis is committed to sharing access to patient-level data with qualified external researchers and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. Result summaries have been posted on the Novartis clinical trial database and other online public databases. More information on Novartis’ position on access to clinical trial results and patient-level data is available here: https://www.novartis.com/our-science/clinical-trials/clinical-trial-information-disclosure.

Acknowledgments
The authors were assisted in the preparation of the manuscript by Delia Randall (Novartis Product Lifecycle Services), who provided writing and editorial support, funded by Novartis Pharma AG in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Novartis was responsible for the conception and design of the study and analysis and interpretation of data. The authors thank the patients who took part in the study and the staff at the participating clinical centers. This study was published as an abstract and presented at the British Thoracic Society Winter Meeting 2014, London, UK, December 3–5, 2014. Insaf Respiratory Research Institute has received compensation for design and performance of clinical trials from Almirall, AstraZeneca, Berlin Chemie, Boehringer, Chiesi, Cytos, Mundipharma, Novartis, Pohl Boskamp, and Zentiva. The institution has received compensation for speaker activities in scientific meetings supported by Almirall, AstraZeneca, Berlin Chemie, Boehringer, Cytos, ERT, GSK, Novartis, Pfizer, Pohl Boskamp, and Takeda. The institution has further received compensation for design and performance of clinical trials from Almirall, Altana/Nycomed, AstraZeneca, Boehringer, Cytos, GSK, Infinity, Medapharma, MSD, Mundipharma, Novartis, Parexel, Pearl Therapeutics, Pfizer, Revotar, Teva, Sterna, and Zentiva. The Pulmonary Research Institute at LungClinic Grosshansdorf received reimbursement from Novartis for conducting this study. The Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research received compensation for participation in clinical studies from AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, GSK, Novartis, Roche, Sanofi, and Takeda. IKF Pneumologie, Clinical Research Centre Respiratory Diseases received reimbursement from Novartis for conducting this study. Division of Pulmonology and UCT Lung Institute, University of Cape Town received reimbursement from Novartis for conducting this clinical trial.

Author contributions
All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
AMT, BH and AR are employees of Novartis Pharma AG. WC is an employee of Novartis Pharmaceuticals Corporation. KMB declares that no personal payments were received from any pharmaceutical entity in the past 5 years. KMB and JB are full-time employees of Insaf Respiratory Research Institute. AMK is an employee of the Pulmonary Research Institute at LungClinic Grosshansdorf. AMK received speaking honoraria, honoraria for participation in advisory board meetings, and travel support for attending congresses in respiratory medicine from Boehringer Ingelheim, AstraZeneca, and Novartis. RNVZS has received honoraria for academic work from Novartis, AZ, CIPLA, ASPEN, Pfizer, GSK, and MSD. The authors report no other conflicts of interest in this work.

References


